Scarica l'app Stockscreener
57.43
1.54%
-0.90
Dopo l'orario di chiusura:
57.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$58.33
Aprire:
$58.33
Volume 24 ore:
1.63M
Relative Volume:
0.65
Capitalizzazione di mercato:
$14.23B
Reddito:
$2.38B
Utile/perdita netta:
$833.42M
Rapporto P/E:
19.03
EPS:
3.0172
Flusso di cassa netto:
$917.69M
1 W Prestazione:
-2.88%
1M Prestazione:
+8.44%
6M Prestazione:
+39.09%
1 anno Prestazione:
+52.33%
Intervallo 1D:
$57.23
$58.33
Intervallo di 1 settimana:
$56.95
$59.41
Portata 52W:
$33.76
$59.72
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
57.43 | 14.45B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Discipline and Rules-Based Execution in EXEL Response - Stock Traders Daily
Adagene earns milestone under Exelixis ADC collaboration - BioWorld News
Adagene Inc. Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - marketscreener.com
Adagene Receives Milestone Payment From Exelixis - marketscreener.com
Exelixis at Citigroup summit: building a second growth engine - Investing.com
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo! Finance Canada
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
A cancer-drug milestone brings Adagene a $2 million payment - Stock Titan
Transcript : Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11 - marketscreener.com
Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026) - JD Supra
Exelixis at Wells Fargo conference: zanzalintinib takes center stage By Investing.com - Investing.com Canada
Exelixis Stock Price Forecast. Should You Buy EXEL? - StockInvest.us
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Exelixis stock hits all-time high at 57.68 USD By Investing.com - Investing.com Australia
EXEL - Finviz
Exelixis stock hits all-time high at 57.68 USD - Investing.com
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2026 - BioSpace
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
Exelixis secures Cabometyx exclusivity with patent win - BioWorld News
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data - Seeking Alpha
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win - Life Sciences IP Review
Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win - Law360
Exelixis wins appeals court ruling upholding key patents, FDA approval barred until at least Jan 15, 2030 - TradingView
Exelixis Wins Appeal in Patent Case Against MSN Laboratories - marketscreener.com
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win - GuruFocus
Exelixis Says U.S. Court Of Appeals For Federal Circuit Affirms Key Portion Of 2024 Judgment In Co's Favor - TradingView
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories - Business Wire
Exelixis Preserves Win Over MSN on Cabometyx Cancer Drug Patents - Bloomberg Law News
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Through Biotechnology with High Return on Equity - DirectorsTalk Interviews
Strong Sales, Earnings Send Exelixis Shares Higher - Yahoo Finance
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition - Trefis
Here's Why Exelixis (EXEL) is a Strong Value Stock - Eastern Progress
NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL - MarketBeat
51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC - MarketBeat
BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL - MarketBeat
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - The Daily Tribune News
FARALLON CAPITAL MANAGEMENT, L.L.C. Buys More Exelixis Inc (EXEL - GuruFocus
BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" - MarketBeat
Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL - MarketBeat
Out of sight, out of work? What’s driving remote job cuts - BioSpace
Investigation launched into EXELIXIS officers f... - Pluang
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - PR Newswire
Exelixis Inc : BMO Initiates Coverage With Ma - Moomoo
EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54 - Bitget
BMO initiates Exelixis stock at Market Perform, cites patent cliff By Investing.com - Investing.com Australia
EXEL Initiates Coverage On BMO Capital -- Price Target Announced at $54.00 - GuruFocus
BMO initiates Exelixis stock at Market Perform, cites patent cliff - Investing.com
JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL - MarketBeat
AQR Capital Management Trims Exelixis Inc (EXEL) Stake -- Shares Trade 16% Above GF Value - GuruFocus
EXEL Looks 16.3% Overvalued on GF Value™ - GuruFocus
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):